Prolia® Postmarketing Active Safety Surveillance Program for Soliciting Adverse Events of Special Interest in the United States (PASP-EMR Program)

16/01/2017
22/02/2024
EU PAS number:
EUPAS17198
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

20090601Protocol Amend 2 2016 Fully Redacted

English (555.62 KB - PDF) View document
Updated protocol

20090601Protocol Amend 2 2016-06-23

First published: 22/02/2024
English (2.84 MB - PDF) View document
Study results
Study results

denosumab 20090601 Observational Final Analysis Abstract

English (216.32 KB - PDF) View document
Study report
Other information